EU drug and device regulators have joined hands to issue guidance on the factors that companies should consider when undertaking clinical trials using diagnostic assays, including combined trials for the development of companion diagnostics (CDx).
Regulations on clinical trials and IVDs in the EU have both undergone significant change recently and the guideline, issued in a Q&A format, clarifies “certain interfaces” between:
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?